134 related articles for article (PubMed ID: 3034797)
1. An analysis of poor risk assignment in patients with germ cell tumours.
Bosl GJ; Bajorin D; Geller NL
Int J Androl; 1987 Feb; 10(1):285-9. PubMed ID: 3034797
[TBL] [Abstract][Full Text] [Related]
2. Management of germ cell tumors of the adult testis at the Memorial Sloan Kettering Cancer Center.
Whitmore WF; Bosl G
Acta Urol Belg; 1985; 53(2):341-61. PubMed ID: 2990181
[No Abstract] [Full Text] [Related]
3. Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
Bosl GJ; Geller NL; Bajorin D
Semin Oncol; 1988 Aug; 15(4):339-44. PubMed ID: 2841764
[No Abstract] [Full Text] [Related]
4. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
5. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for metastatic testicular germ cell tumours: the Memorial Sloan-Kettering cancer model.
Bosl GJ
Eur Urol; 1993; 23(1):182-7. PubMed ID: 8386647
[TBL] [Abstract][Full Text] [Related]
7. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with non-seminomatous germ cell tumours stage I.
Rørth M; Cullen MH; Horwich A; Roth BJ
Prog Clin Biol Res; 1990; 357():295-303. PubMed ID: 2170995
[No Abstract] [Full Text] [Related]
9. Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors.
Bosl GJ; Geller NL; Bajorin D
Cancer; 1991 Mar; 67(5):1299-304. PubMed ID: 1846774
[TBL] [Abstract][Full Text] [Related]
10. The management and outcome of patients with germ-cell tumours treated in the Edinburgh Cancer Centre between 1988 and 2002.
Howard GC; Conkey DS; Peoples S; McLaren DB; Hargreave TB; Tulloch DN; Walker W; Kerr GR
Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):435-40. PubMed ID: 16149287
[TBL] [Abstract][Full Text] [Related]
11. Compliance of males with stage 1 testicular germ cell tumours on an active surveillance protocol.
Honeyball F; Murali-Ganesh R; Hruby G; Grimison P
Intern Med J; 2015 Oct; 45(10):1081-4. PubMed ID: 26429219
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts in the management of clinical stage I nonseminomatous testicular cancer: significance of prognostic factors.
Javadpour N
J Urol; 1985 Aug; 134(2):427. PubMed ID: 2991615
[No Abstract] [Full Text] [Related]
13. Update on the management of patients with intermediate and poor-risk testicular germ cell tumors and new biological insights.
Mérida-García A; Díaz-Serrano A; Bernard B; Del Mar Galera M; de Velasco G; Sepúlveda JM; Fernández L; Medina J; Castellano D
Cancer Treat Res Commun; 2019; 19():100117. PubMed ID: 30684681
[No Abstract] [Full Text] [Related]
14. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration.
Kildahl-Andersen A; Erke MG; Sagstuen H; Bremnes RM
Acta Oncol; 2005; 44(6):537-44. PubMed ID: 16165912
[TBL] [Abstract][Full Text] [Related]
15. Re: Prognostic assessment in nonseminomatous testicular cancer: implications for therapy.
Hoeltl W
J Urol; 1991 Dec; 146(6):1619-20. PubMed ID: 1658402
[No Abstract] [Full Text] [Related]
16. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors and results of treating 42 patients with nln-seminomatous germ cell tumor of the testis].
Czownicki Z; Rogozińska J; Choina B
Pol Tyg Lek; 1996 Feb; 51(6-9):82-5. PubMed ID: 8756738
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of advanced testicular cancer.
Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
[TBL] [Abstract][Full Text] [Related]
19. [Bilateral testicular tumors].
Cerný V; Scheinar J
Rozhl Chir; 1990 Nov; 69(11):726-9. PubMed ID: 1967026
[TBL] [Abstract][Full Text] [Related]
20. How should we identify high risk testicular tumour patients? Round table discussion.
Grigor KM; Schmoll HJ
Eur Urol; 1993; 23(1):207-12. PubMed ID: 8386651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
